Literature DB >> 4023172

Parathyroidectomy in chronic renal failure.

A M de Francisco, H A Ellis, J P Owen, M J Cassidy, J R Farndon, M K Ward, D N Kerr.   

Abstract

In order to establish whether parathyroidectomy altered the natural history of ectopic calcification in patients with renal failure we undertook a detailed analysis of 62 patients with hyperparathyroidism secondary to chronic renal failure who were submitted to parathyroidectomy. Biochemical data (61 patients) and radiological skeletal surveys (42 patients) were studied before and after parathyroidectomy. Transiliac bone biopsies were obtained at (or some time in the previous six months before) parathyroidectomy in 30 and in 36 patients after surgery. Paired bone biopsies were available from 17 of these patients. In the majority of patients secondary hyperparathyroidism was controlled after parathyroidectomy although in seven patients (11 per cent), who underwent subtotal parathyroidectomy, it relapsed after initial improvement. Non-visceral soft tissue calcification disappeared or decreased in 60 per cent of the patients after parathyroidectomy. However, despite marked improvement in subperiosteal erosions and histological osteitis fibrosa, with significant reductions in iPTH and Ca X P product after parathyroidectomy, small peripheral arterial calcification developed or progressed in 56 per cent of the patients. Histological osteomalacia after parathyroidectomy developed after operation in two patients. Both had positive aluminium stains for excess aluminium in their bone. Numbers of osteoclasts and the amount of marrow fibrosis declined in parallel following parathyroidectomy, but woven bone persisted for months or years.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4023172

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  8 in total

1.  Klotho deficiency causes vascular calcification in chronic kidney disease.

Authors:  Ming Chang Hu; Mingjun Shi; Jianning Zhang; Henry Quiñones; Carolyn Griffith; Makoto Kuro-o; Orson W Moe
Journal:  J Am Soc Nephrol       Date:  2010-11-29       Impact factor: 10.121

2.  Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

Authors:  Francesca Tentori; Mia Wang; Brian A Bieber; Angelo Karaboyas; Yun Li; Stefan H Jacobson; Vittorio E Andreucci; Masafumi Fukagawa; Luc Frimat; David C Mendelssohn; Friedrich K Port; Ronald L Pisoni; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

3.  Tertiary hyperparathyroidism associated with metastatic cardiac calcification in a haemodialyzed patient.

Authors:  S Fujimoto; S Hisanaga; Y Yamatomo; K Tanaka; T Hayashi; A Sumiyoshi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

4.  Tumoral calcinosis revisited: pathophysiology and treatment.

Authors:  Gregor Möckel; Frank Buttgereit; Karsten Labs; Carsten Perka
Journal:  Rheumatol Int       Date:  2003-09-12       Impact factor: 2.631

5.  Secondary hyperparathyroidism: diagnosis of site of recurrence.

Authors:  D Casanova; E Sarfati; A De Francisco; J A Amado; M Arias; C Dubost
Journal:  World J Surg       Date:  1991 Jul-Aug       Impact factor: 3.352

6.  The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients.

Authors:  Francesca Tentori; Lindsay Zepel; Douglas S Fuller; Mia Wang; Brian A Bieber; Bruce M Robinson; Ronald L Pisoni
Journal:  Am J Kidney Dis       Date:  2015-09       Impact factor: 8.860

Review 7.  Parathyroid gland function in secondary hyperparathyroidism.

Authors:  I B Salusky; W G Goodman
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

Review 8.  Klotho: a humeral mediator in CSF and plasma that influences longevity and susceptibility to multiple complex disorders, including depression.

Authors:  M G Pavlatou; A T Remaley; P W Gold
Journal:  Transl Psychiatry       Date:  2016-08-30       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.